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TEAbstract
The adaptation of existing antimalarial nanocarriers to new Plasmodium stages, drugs, targeting molecules, or encapsulating structures is
a strategy that can provide new nanotechnology-based, cost-efficient therapies against malaria. We have explored the modification of
different liposome prototypes that had been developed in our group for the targeted delivery of antimalarial drugs to Plasmodium-infected
red blood cells (pRBCs). These new models include: (i) immunoliposome-mediated release of new lipid-based antimalarials; (ii) liposomes
targeted to pRBCs with covalently linked heparin to reduce anticoagulation risks; (iii) adaptation of heparin to pRBC targeting of chitosan
nanoparticles; (iv) use of heparin for the targeting of Plasmodium stages in the mosquito vector; and (v) use of the non-anticoagulant
glycosaminoglycan chondroitin 4-sulfate as a heparin surrogate for pRBC targeting. The results presented indicate that the tuning of existing
nanovessels to new malaria-related targets is a valid low-cost alternative to the de novo development of targeted nanosystems.
© 2016 Published by Elsevier Inc.
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Antimalarial drugs can potentially target a suite of pathogen
life stages inside two different hosts: humans and the insect
vectors. Infection starts when a parasitized female Anopheles
mosquito inoculates sporozoites of the malaria parasite, the
protist Plasmodium spp., into a person while taking a blood
meal. Within a few minutes, sporozoites have migrated through
the skin and bloodstream to the liver, where they invade
hepatocytes. Sporozoites develop into merozoites,1 which enter
the circulation, invade red blood cells (RBCs),2 and replicate
asexually to produce daughter cells that invade new RBCs to
perpetuate the blood-stage cycle unfolding through ring,
trophozoite, and schizont stages. Some parasites eventually
differentiate into sexual stages, female and male gametocytes
that are ingested by a mosquito from peripheral blood. When an
infected bloodmeal reaches the insect's midgut, micro- and
macrogametocytes develop into male and female gametes.
Following fertilization, the zygote differentiates into an ookinete
that moves through the midgut epithelium and forms an oocyst,
which releases sporozoites. The malaria transmission cycle is
restarted when sporozoites migrate to the salivary glands and are
injected into a human with the mosquito's next bite.
With malaria elimination now firmly on the global research
agenda, but resistance to the currently available drugs on the rise,
there is an urgent need to invest in research and development of
new therapeutic strategies.3 Encapsulation of drugs in targeted
nanovectors is a rapidly growing area with a clear applicability to
infectious disease treatment,4 and pharmaceutical nanotechnol-
ogy has been identified as a potentially essential tool in the future
fight against malaria.5,6 Nanoparticle-based targeted delivery
approaches can play an important role for the treatment of
malaria because they might allow (i) low overall doses that limit
the toxicity of the drug for the patient, (ii) administration of
sufficiently high local amounts to minimize the evolution of
resistant parasite strains,7 (iii) improvement of the efficacy of
currently used hydrophilic (low membrane trespassing capacity)
and lipophilic antimalarials (poor aqueous solubility), and (iv)
use of orphan drugs never assayed as malaria therapy, e.g.
because of their elevated and wide-spectrum toxicity. In the very
nature of nanovectors resides their versatility that enables
assembling several elements to obtain chimeric nanovessels
tailored to fit the requirements for different administration routes,
particular intracellular targets, or combinations of drugs.
One of the limitations of liposomes as carriers for drug
delivery to Plasmodium-infected RBCs (pRBCs) is that because
of the lack of endocytic processes in these cells, a relatively fluid
liposome lipid bilayer is required to favor fusion events with the
pRBC plasma membrane. As a result, these liposomes are leaky
for small drugs encapsulated in their lumen,8 and when
membrane fusion occurs, only a relatively small fraction of
the originally contained drug is delivered into the cell. On the
other hand, liposomes made of saturated lipids have less fluid
bilayers that retain drugs with high efficacy,8 although fusion
events with pRBC membranes are greatly diminished, which
might also reduce the amount of luminal cargo delivered to the
target cell. The so-called combination therapies, where several
drugs are simultaneously administered,9 significantly improve
the antimalarial effect of the individual compounds. Liposomes
are particularly adept structures in this regard because theyTE
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allow the encapsulation of hydrophobic molecules in their lipid
bilayer and of water-soluble compounds in their lumen, thus
being a potentially interesting platform for combination
therapies where lipophilic and hydrophilic drugs are delivered
together.
One of the main pRBC-binding molecules are glycosamino-
glycans (GAGs), some of whose members include heparin,
heparan sulfate (HS), and chondroitin sulfate (CS). Chondroitin
4-sulfate (CSA) has been found to act as a receptor for pRBC
binding in the microvasculature and the placenta,10 and
adhesion of pRBCs to placental CSA has been linked to the
severe disease outcome of pregnancy-associated malaria.11
pRBC adhesion to the endothelium of postcapillary venules is
mediated by the parasite-derived antigen Plasmodium falci-
parum erythrocyte membrane protein 1 (PfEMP1),12 whereas
CSA has been identified as the main receptor for PfEMP1
attachment to placental cells.10,13 Single-molecule force
spectroscopy data have revealed a complete specificity of
adhesion of heparin to pRBCs vs. RBCs, with a binding strength
matching that of antibody–antigen interactions.14 Heparin had
been used in the treatment of severe malaria,15 but it was
abandoned because of its strong anticoagulant action, with side
effects such as intracranial bleeding. It has been shown that
heparin electrostatically bound to liposomes acts as an antibody
surrogate, having a dual activity as a pRBC-targeting molecule
but also as an antimalarial drug in itself acting mainly on
trophozoite and schizont stages.16 Because heparin is signifi-
cantly less expensive to obtain than specific (monoclonal)
antibodies, the resulting heparin-liposomes have a cost about ten
times lower than that of equally performing immunoliposomes.
A question that remains open is whether the heparin-mediated
targeting of liposomes to pRBCs could be extended to other
glycosaminoglycans, to different Plasmodium stages, and to
new nanoparticle types.
Through modification of its component elements, the
nanovector design is susceptible to improvement and adaptation
to new targets such as different Plasmodium species or infected
cells other than the erythrocyte. Of particular interest here is the
targeting of the transmission stages that allow transfer of the
parasite between human and mosquito and vice-versa, which
represent the weakest spots in the life cycle of the pathogen.17
Heparin and HS are targets for the circumsporozoite protein in
sporozoite attachment to hepatocytes during the primary stage
of malaria infection in the liver.18 CS proteoglycans in the
mosquito midgut and synthetic CS mimetics have been
described to bind Plasmodium ookinetes as an essential step
of host epithelial cell invasion,19,20 whereas ookinete-secreted
proteins have significant binding to heparin.21 This body of
accumulated evidence suggests that GAGs might be adequate to
target antimalarial-loaded nanovectors to Plasmodiummosquito
stages, either through a direct entry into ookinetes and
sporozoites, or indirectly through delivery to pRBCs for those
pRBCs that will eventually differentiate into gametocytes.
Here we have explored whether the heparin- and
antibody-mediated targeting of drug-containing liposomes to
pRBCs could be adapted in a straightforward way to other GAGs
as targeting molecules, to different Plasmodium stages as target
cells, and to new nanoparticle and drug types.
F146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
3J. Marques et al / Nanomedicine: Nanotechnology, Biology, and Medicine xx (2016) xxx–xxxMethods
Materials
Except where otherwise indicated, reactions were performed at
room temperature (20 °C), reagents were purchased from
Sigma-Aldrich Corporation (St. Louis, MO, USA), and cultures
of the P. falciparum 3D7 strain have been used. The lipids (all
≥99% purity according to thin layer chromatography analysis)
1,2-dioleoyl- sn -glycero-3-phosphocholine (DOPC),
L-α-phosphatidylethanolamine (PE), 1,2-dipalmitoyl-sn-glycero-3-
phosphoethanolamine-N-(4-(p-maleimidophenyl)butyramide
(MPB-PE), 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N
(lissamine rhodamine B sulfonyl) (DOPE-Rho), and
1,2-dioleoyl-3-trimethylammonium-propane (DOTAP) were pur-
chased from Avanti Polar Lipids Inc. (Alabaster, AL, USA).O
O
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200
Figure 1. Determination of the concentration-dependent effect of the lipid
MPB-PE on the in vitro growth of P. falciparum. Concentrations of the liposome
formulations in the cultures were 200 μM lipid except where otherwise indicated.Liposome preparation
Established protocols were used for liposome22 and immuno-
liposome preparation.23 In Supplementary Video 1 can be seen an
example of a pRBC culture treated with rhodamine-labeled
immunoliposomes targeted to pRBCs as described elsewhere.23
Liposome size was determined by dynamic light scattering using a
Zetasizer NanoZS90 (Malvern Ltd., Malvern, UK).T
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Preparation of primaquine-containing liposomes functionalized
with covalently bound heparin
The antimalarial drug primaquine (PQ) was encapsulated in
DOTAP-containing liposomes (DOPC:PE:cholesterol:DOTAP,
46:30:20:4) by dissolving it at 1.2 mM in the PBS buffer used to
hydrate the lipids, removing non-encapsulated drug by ultracen-
trifugation (150,000×g, 1 h, 4 °C). To crosslink the amine groups
present in the liposomes with the carboxyl groups of heparin
(sodium salt from porcine intestinal mucosa, 13 kDa mean
molecular mass) or its hexa- and octasaccharide fragments
(Iduron,Cheshire,UK), the polymerswere first dissolved at 1mg/mL
in MES activation buffer (0.1 M 2-(N-morpholino)ethane sulfonic
acid, 0.5 M NaCl, pH 5.0). Final concentrations of 2 mM
N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride
(EDC, Fluka) and 5 mM N-hydroxysuccinimide (NHS, Fluka)
were added to the activated heparin solution. To obtain the desired
heparin: liposome ratios, after 15 min the corresponding heparin
solution and liposome suspension volumes in PBSbufferweremixed
and incubated for 2 h with gentle stirring. To remove unbound
heparin, liposomes were pelleted by ultracentrifugation (150,000×g,
1.5 h, 4 °C), and taken up in 10 pellet volumes of PBS immediately
before addition to pRBC cultures with a further ca. 20-fold dilution
(to obtain 3 μM final PQ concentration in the culture). For the
quantification of encapsulated PQ, a lipid extraction of the liposomes
was performed. Briefly, following ultracentrifugation the liposome
pellet was treatedwithmethanol:chloroform:0.1MHCl (1.8:2:1) and
after phase separation the PQ content in the upper water–methanol
phase was determined by measuring A320 against a calibration curve
of known PQ concentrations. In vitro coagulation tests of
heparin-containing liposomes were done as previously described.16
Heparin concentration was determined by the Alcian Blue method.24E
D
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R
Chitosan nanoparticle synthesis
Chitosan nanoparticles were prepared by a coacervation
method described elsewhere.25 Briefly, 0.5 g chitosan (low
molecular weight, 75-85 deacetylated, Aldrich Ref. 448869) was
dissolved in 50 mL of an aqueous solution of 2% v/v acetic acid
containing 1%w/v Pluronic® F-68. About 12.5 mL of a 20% w/v
sodium sulfate solution was added dropwise (2.5 mL/min) to the
chitosan solution under mechanical stirring (1200 rpm) for 1 h to
obtain a suspension of chitosan nanoparticles. The colloidal
suspension was then subjected to a cleaning procedure that
included repeated cycles of centrifugation (40 min, 14,000×g;
Centrikon T-124 high-speed centrifuge, Kontron, Paris, France)
and re-dispersion in water, until the conductivity of the
supernatant was ≤10 μS/cm. Particle size was determined by
photon correlation spectroscopy using a Malvern 4700 analyzer
(Malvern Ltd). The measurement was made under a 60° scattering
angle of the aqueous nanoparticle suspensions (0.1%, w/v). The
electrophoretic mobility measurements were performed in 0.1%
(w/v) aqueous suspensions of nanoparticles in 1 mM KNO3,
pH 7, using a Malvern Zetasizer 2000 electrophoresis device
(Malvern Ltd), under mechanical stirring (50 rpm) at 25 °C. The
electrophoretic mobility was converted into zeta potential (ζ, mV)
values as described by O′Brien and White.26
Determination of chitosan–heparin interaction
Isothermal titration calorimetry (ITC) measurements were
performed with a VP-ITC microcalorimeter following estab-
lished protocols.16 For fluorescence determinations, chitosan
nanoparticles (5 mg/mL) and heparin labeled with fluorescein
isothiocyanate (heparin-FITC, Life Technologies) were mixed
10:1 w/w and incubated for 90 min with gentle orbital mixing.
After a centrifuge step (100,000×g, 1 h, 4 °C) to remove
unbound heparin, the pellet was taken up in PBS, its fluorescence
measured (λex/em: 488/525 nm), and the corresponding concen-
tration determined against a standard linear regression of known
FITC concentrations. The fluorescence of the supernatant was
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Figure 2. Fluorescence confocal microscopy analysis of the fate of Rho-labeled lipids incorporated in the formulation of pRBC-targeted immunoliposomes
added to living P. falciparum cultures and incubated for 90 min before proceeding to sample processing. Arrows indicate pRBCs and arrowheads RBCs.
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not associated with the nanoparticles.
Plasmodium falciparum cell culture
The P. falciparum strains 3D7 and CS2 (MRA-96, obtained
through the MR4 as part of the BEI Resources Repository,
NIAID, NIH, deposited by SJ Rogerson) were grown in vitro in
group B human RBCs using previously described conditions.27
Plasmodium berghei ookinete culture and targeting assay
Ookinete culture medium consisted of 16.4 g/L Roswell Park
Memorial Institute (RPMI) medium supplemented with 2% w/v
NaHCO3, 0.05% w/v hypoxanthine, 100 μM xanthurenic acid,
50 U/mL penicillin, 50 μg/mL streptomycin (Invitrogen), 25 mM
HEPES, pH 7.4. Complete medium was prepared just before use
by supplementing with heat-inactivated fetal bovine serum (FBS,
Invitrogen) to a final concentration of 20%. Six days prior to
performing the targeting assay, a mouse was treated intraperi-
toneally with 10 μg/mL phenylhydrazine (PHZ) to inducereticulocytosis. Three days after PHZ treatment the mouse was
inoculated by intraperitoneal injection of 200 μL of blood
containing ca. 5 × 107 P. berghei mCherry (a kind gift from
Dr. D. Vlachou) pRBCs extracted by cardiac puncture from a
donor mouse that had been infected intraperitoneally 3 days before
with 200 μL of a cryopreserved P. berghei suspension just thawed.
Three days later, 1 mL of infected blood was collected by cardiac
puncture onto 30 mL ookinete medium, and incubated for 24 h at
19-21 °C with 70-80% relative humidity. For ookinete targeting
assays, 100 μL of 0.25 mg/mL heparin-FITC was added to 100 μL
of culture and incubated in the dark for 90min under orbital stirring
(300 rpm). The samples were centrifuged for 1.5 min at 800×g
and washed 3× with PBS. Fixed cell slides were prepared by
adding 0.5 μL FBS to 0.5 μL pellet and by fixing the smear
with 4% paraformaldehyde for 15 min. After performing 3
washing steps with PBS, slides were mounted with Vectashield®
4′6-diamino-2-phenylindole (DAPI)-containing media (Vector
Laboratories, UK). All work involving laboratory animals was
performed with humane care in accordance with EU regulations
(EU Directive 86/609/EEC) and with the terms of the United
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Figure 3. Fluorescence confocal microscopy analysis of a pRBC showing the subcellular distribution of Rho-labeled lipids incorporated in the formulation of
pRBC-targeted immunoliposomes added to living P. falciparum cultures. Arrowheads indicate structures compatible with plasma membrane-liposome merging
events.
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KingdomAnimals (Scientific Procedures) Act (PPL 70/8788), and
was approved by the Imperial College Ethical Review Committee.
Microscopy
Existing protocols were used for the fluorescent labeling of
CSA,28 fluorescence confocal microscopy16 and cryo-transmission
electron microscopy29 sample imaging. Details of these techniques
are provided in the Supplementary Materials.
Force spectroscopy
Binding forces between CSA and pRBCs infected with the
P. falciparum CS2 strain were measured by atomic force
microscope (AFM) single-molecule force spectroscopy (SMFS)
essentially as described elsewhere.14 A complete protocol is
provided in the Supplementary Materials.
Statistical analysis
Data are presented as the mean ± standard deviation of at
least three independent experiments, and the corresponding
standard deviations in histograms are represented by error bars.
The parametric Student's t test was used to compare two
independent groups when data followed a Gaussian distribution,
and differences were considered significant when P ≤ 0.05.
Percentages of viability were obtained using non-treated cells ascontrol of survival and IC50 values were calculated by nonlinear
regression with an inhibitory dose–response model using
GraphPad Prism5 software (95% confidence interval). Concen-
trations were transformed using natural log for linear regression,
and regression models were adjusted for the assayed replicates.Results
Use of targeted liposomes for the delivery of antimalarial lipids
to plasmodium
Preliminary data suggesting antimalarial activity of certain
lipids23 led us to explore this observation in more detail. The
lipid MPB-PE, used for the covalent crosslinking to liposomes of
antibodies through thioether bonds, exhibited significant
concentration-dependent inhibition of the in vitro growth of
P. falciparumwhen incorporated in the formulation of liposomes
(Figure 1). This antiparasitic effect suggested that, upon random
interactions of liposomes with pRBCs, lipids entered the cell and
reached the pathogen. To explore whether such process occurred
through whole liposome entry or was mediated by transfer
phenomena between the apposed lipid bilayers of liposomes and
pRBCs, we performed confocal fluorescence microscopy
analysis of pRBC-targeted immunoliposomes containing in
their formulation 7% of the rhodamine-tagged lipid
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Figure 4. Antimalarial activity and targeting capacity of different amounts of
heparin covalently bound to primaquine-containing liposomes (LP-PQ-Hep).
Controls include plain liposomes (LP), heparin-free, primaquine-containing
liposomes (LP-PQ) and primaquine-free liposomes targeted with covalently-
bound heparin (LP-Hep). PQ concentration in the pRBC culture was 3 μM
for all samples. In parentheses are indicated the determined μg/mL of
liposome-bound heparin present in P. falciparum cultures.
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DOPE-Rho. Specific pRBC targeting was achieved as previously
described23 through functionalization of the liposomes with the
monoclonal antibody BM1234 raised against the P. falcipar-
um-expressed membrane-associated histidine-rich protein 1.8
The results obtained with P. falciparum cultures containing
RBCs and 5% pRBCs (Figure 2) showed that targeted
liposome-administered lipids were specifically delivered to
pRBCs and after 90 min of incubation colocalized with
intracellular parasites. The observation of diffuse fluorescence
and the lack of punctate patterns characteristic of whole intact
liposomes8 suggests that upon contact with the pRBC plasma
membrane, liposomes fused with the cell and their constituent
lipids were incorporated by the growing parasites. Whole
liposome entry into pRBCs might theoretically occur through
the reported tubulovesicular network induced by Plasmodium
during its intraerythrocytic growth,30 which extends from the
parasitophorous vacuole membrane and connects the intracellu-
lar parasite with the host RBC surface. However, this confers to
the pRBC the capacity of internalizing a wide range of particles
up to diameters of only 70 nm,30,31 well below the mean size of
the liposomes used here (N140 nm, Figure S1). Higher resolution
images of cells prepared at earlier stages in the drug delivery
process revealed phenomena consistent with the interaction of
liposomes with pRBCs immediately before or just after their
constituent lipids are incorporated into the cell plasma membrane
(Figure 3).
Antimalarial activity of drug-loaded liposomes targeted with
covalently bound heparin
The dual activity of heparin as an antimalarial drug and as the
pRBC targeting element has been proposed as a promising newTE
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avenue for future malaria therapies.32 However, existing models
contain electrostatically bound heparin16 that is prone to peel off
from liposome surfaces while in the blood circulation, incurring
the risk of anticoagulation and internal bleeding. To explore
strategies that could minimize these adverse effects, we have
modified our previous design to incorporate covalently bound
heparin on primaquine (PQ)-loaded liposomes. PQ was selected
because its high IC50 for in vitro P. falciparum cultures allowed
an immediate and easy sample concentration determination, but
also for reasons regarding current needs in antimalarial
chemotherapy. In patients with glucose-6-phosphate dehydro-
genase (G6PD) deficiency PQ generally induces RBC oxidative
damage that eventually results in hemolytic anemia which may
be severe.33,34 Such toxicological concerns have led to
restrictions in the use of this drug since the incidence of G6PD
genetic anomaly is particularly high in areas where malaria is
endemic,35 a situation that calls for new methods addressed to
the targeted delivery of PQ active species to pRBCs. The new
liposome prototype exhibited an additive effect whereby
PQ-loaded liposomes had a significantly improved antimalarial
activity when targeted with covalently bound heparin (Figure 4),
suggesting the double role of this GAG as drug and targeting
molecule. The anticoagulant activity of heparin covalently bound
to liposomes (Table 1) was found to be significantly smaller than
similar amounts electrostatically bound,16 in agreement with
previous evidence of non-anticoagulant activity of heparin when
covalently immobilized on a substrate.36
Depolymerized heparin lacking anticlotting activity had been
found to disrupt rosette formation and pRBC cytoadherence
in vitro and in vivo in animal models and in fresh parasite
isolates.37,38 Shorter heparin fragments consisting of hexa- and
octasaccharides (dp6 and dp8; Figure 5, A) having insignificant
anticoagulant activity39 exhibited a much smaller antimalarial
activity in vitro than the native polymer, with respective IC50s of
174 and 134 μg/mL, compared to around 4 μg/mL for heparin
(Figure 5, B). Neither heparin oligosaccharide covalently bound
to PQ-loaded liposomes improved the activity of the liposomized
drug (data not shown), suggesting that also the pRBC targeting
capacity of heparin is significantly lost upon depolymerization.
Functionalization of chitosan nanoparticles with heparin
The highly specific binding of heparin to pRBCs vs. RBCs14
prompted us to explore its capacity as a targeting agent of
nanoparticles other than liposomes. The electrostatic interaction
of heparin with positively charged nanocapsules has been
explored as a proof of concept with the objective of designing
the simplest functionalization strategy. ITC was used to analyze
the interaction of heparin with the cationic polymer chitosan
(Figure 6), whose biocompatibility makes it a preferred material
for biomedical applications.40–42 A complete sigmoidal exo-
thermic binding isotherm for the interaction heparin–chitosan
was observed, with a 50% saturation obtained at a molar ratio
chitosan:heparin of 0.25 and a binding constant of 7.9 ±
0.6 × 103 M−1 fitted to a model of identical binding sites
(Figure 6, A). Chitosan nanoparticles were synthesized with an
average diameter of 140 ± 30 nm (Figure 6, C) and a positive
surface charge (zeta potential, ζ, of 18 ± 4 mV at 25 °C and pH
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Table 1t1:1
In vitro coagulation test of different heparin concentrations, free or covalently
conjugated to liposomes.t1:2
Free heparin 
250 µM liposomes-heparin
(determined heparin content)
PBS, no heparin 101.0 101.0
20 µg/mL heparin <25 114.2 (6.0 µg/mL) 
4 µg/mL heparin 64.1 109.4 (1.2 µg/mL) 
1 µg/mL heparin 102.9 109.4 (0.3 µg/mL) 
Liposome preparations initially containing the same heparin amounts as
liposome-free samples were ultracentrifuged to remove unbound heparin
and the new heparin content was experimentally determined; the values
indicated in parentheses correspond to actual heparin concentrations in
P.falciparum cultures that result from adjusting the volume of liposome
suspension added to obtain a final 3 μMPQ. Coagulation capacity is expressed
as a percentage relative to the value obtained with standard human plasma.
Shadowed in gray are indicated those samples with anticoagulant activity.t1:3 Figure 5. In vitro antimalarial activity of heparin fragments compared to that
of heparin. (A) Chemical structure of the hexa- and octasaccharides dp6 and
dp8. (B) P. falciparum growth inhibition assay.
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7.0). When heparin was added to chitosan nanoparticles a strong
cooperative effect was observed with a 3 orders of magnitude
increase for the binding constant (4.6 ± 2.6 × 106 M−1) fitted
to the same binding model (Figure 6, B). Likely, the association
of multiple chitosan molecules in a nanoparticle favored the
cooperative binding of heparin to adjacent chitosan chains
following an initial interaction. In pull-down assays where
0.5 mg/mL heparin-FITC was mixed with chitosan nanoparticles
at a 1:10 w/w ratio, 93% of heparin was found to be bound to the
pelleted nanoparticles (data not shown). Cryo-transmission
electron microscopy analysis indicated that heparin was not
tightly bound to chitosan nanoparticles, but it rather formed a
loose network around them (Figure S2). According to in vitro
P. falciparum growth inhibition assays the interaction of heparin
with chitosan did not affect its antimalarial activity (Figure 6, D).
Targeting of heparin to plasmodium stages in the mosquito vector
The straightforward binding of heparin to chitosan results in
nanoparticles likely to be innocuous for insects given the
endogenous nature of chitosan in these animals and the expected
imperviousness of mosquitoes to the presence of blood anticlotting
agents. This stimulated us to study the targeting capacity of heparin
towards the Plasmodium stages in Anopheles. Fluorescently
labeled heparin-FITC added to preparations containing Plasmo-
dium gametocytes, ookinetes, oocysts or sporozoites was observed
to bind only to ookinetes (Figures 7 and S3). Here we have
followed the available protocols for ookinete in vitro production
which use the murine malaria parasite P. berghei, although
our results are in agreement with previous data reporting on
P. falciparum ookinete proteins binding heparin,21 condroitin
sulfate GAGs,19 and GAG mimetics.20
Use of CSA for the targeting of pRBCs
As discussed above, the potential use of heparin as drug in
malaria therapy15,43–45 has been hindered by its anticlotting
properties,46 but heparin-related polysaccharides exist which areE
D
 Pknown to have little anticoagulating activity. One suchpolysaccharide is CSA, which lacks antimalarial activity47 but
whose pRBC targeting capacity has barely been explored. We
have used AFM-SMFS to measure the binding forces between
CSA and pRBCs or non-infected RBCs deposited on
poly-L-lysine-coated glass slides. CSA molecules were immo-
bilized on the tip of cantilevers used as force sensors, which were
approached to the adsorbed erythrocytes and retracted from them
after contact in order to obtain a force curve. Single-molecule
CSA-pRBC adhesion forces in PBS were evaluated from the
unbinding events found in ca. 50% to 71% of total retraction
force curves (Figure 8, A). As the CSA-coated tip withdrew, a
decompression and stretching of the pRBC were observed in the
retraction force curves for distances up to 4 μm, which was
followed by a vertical jump (arrows in Figure 8, A) correspond-
ing to the detachment of the tip from the cell membrane. A flat
baseline was finally reached, indicating no interaction between
cell and tip after their complete separation. A representative
histogram for CSA-pRBC adhesion (Figure 8, B) shows an
average binding force of 41 ± 1 pN for the main peak. A second,
smaller peak at 70 ± 17 pN, and possibly a third one at about
120 pN (not included in the fit), could correspond to the
simultaneous unbinding of 2 and 3 interacting groups on the
same or different CSA molecules, respectively. In dynamic force
spectroscopy assays performed at different loading rates, binding
forces between 32 and 51 pN were calculated for the main peaks
of the histograms obtained (Figure 8, C). A linear relation
between binding force and logarithm of loading rate was
observed, in agreement with the predictions from Bell–Evans
model for binary interactions.48,49 Control experiments with
non-infected RBCs showed adhesion to CSA in only a small
proportion (9%-12%) of the retraction force curves, with smaller
binding forces than for pRBCs (e.g. 32 ± 1 pN for the
representative histogram in Figure 8, B). This specificity of
adhesion was confirmed in fluorescence confocal microscopy
assays (Figure 8, D).
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Figure 6. Study of the interaction between heparin and chitosan. (A) Representative data from an ITC experiment in which heparin was titrated into the reaction
cell containing chitosan. Aliquots of a 0.05 mM heparin solution were injected to a 0.01 mM chitosan solution in the ITC cell. The area underneath each injection
peak (top panel) is equal to the total heat released for that injection. When this integrated heat is plotted against the respective molar ratios in the reaction cell, a
complete binding isotherm for the interaction is obtained (bottom panel). (B) Representative data from an ITC experiment in which 1 mg/mL heparin was
injected into the reaction cell containing 0.1 mg/mL chitosan nanoparticles (NPs). (C) Scanning electron microscopy image of the chitosan nanoparticles used.
(D) Effect on the antimalarial activity of heparin of its interaction with chitosan. In heparin + chitosan samples the plotted concentration refers to that of heparin.
Figure 7. Fluorescence confocal microscopy analysis of the binding of heparin-FITC to P. berghei ookinetes in vitro. Ookinete fluorescence is shown by
mCherry and parasite nuclei were stained with DAPI.
8 J. Marques et al / Nanomedicine: Nanotechnology, Biology, and Medicine xx (2016) xxx–xxxThe adhesion between pRBCs infected by the CSA-binding
P. falciparum FCR3-CSA strain and Chinese hamster ovary
(CHO) cells expressing CSA on their surface had been explored
by AFM force spectroscopy,50 yielding a mean rupture force of
43 pN, similar to that obtained here using purified CSA. Because
CSA interaction with pRBCs has been described to occur
through the binding to PfEMP1 on erythrocyte surfaces, the
adhesive force between both cell types had been assignedentirely to the CSA-PfEMP1 association.50 The binding of CSA
on the AFM cantilever to pRBCs could not be inhibited by the
presence of 500 μg CSA/mL in solution (Figure S4), whereas
pRBC-CHO adhesion had been shown to be significantly
blocked (ca. 90% inhibition) by 100 μg CSA/mL.51 This
discrepancy can likely be explained by invoking the much larger
CSA concentration on AFM cantilevers in SMFS assays than on
CHO cell surfaces.
U
N
C
O
R
R
E
C
T
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
Figure 8. Study of CSA binding to erythrocytes. (A) Typical AFM-SMFS
force curves obtained when retracting CSA-functionalized cantilever tips
from pRBCs. Arrows indicate individual CSA-pRBC unbinding events. For
the sake of clarity, the force curves were shifted vertically to avoid
overlapping. (B) Representative force histograms for the binding of CSA to
pRBCs (gray) and RBCs (black) at a loading rate of 24 nN s−1. Force
histograms were fitted to a Gaussian (RBC) or a 2-peak Gaussian function
(pRBC). (C) Average binding forces between CSA and pRBCs at different
loading rates. The dashed line corresponds to the linear fit of the experimental
data. (D) Fluorescence confocal microscopy analysis of the binding in vitro
of fluorescent CSA to living pRBCs infected with the P. falciparum CS2
strain. The phase contrast image in the upper left panel evidences the
presence of several non-infected RBCs in the microscope field. As a pRBC
marker, hemozoin crystal reflection is shown in red in addition to DNA stain.
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Discussion
Despite the lack of economic incentives for research in
nanomedicine applications to malaria a number of liposome- and
polymer-based nanocarriers engineered for the targeted delivery
of antimalarial drugs have been developed.5,6,8,16,23,29,52,53
Although successful efforts have been made to obtain new
nanostructures having affordable synthesis costs while still
exhibiting good performance in lowering the IC50 of drugs,16,29
new approaches are required to further optimize these scarce
resources. The implementation of novel delivery approaches is
less expensive than finding new antimalarial drugs and may
optimize the rate of release of current and future compounds.54
The three elements that constitute a targeted therapeutic
nanovector (nanocapsule, targeting molecule and the drug itself)
can be exchanged, as if they were LEGO blocks, to obtain new
structures better suited to each particular situation.
The data presented here allowus to propose several combinations
of nanovector parts that could be adapted to new antimalarial
strategies: (i) liposomes formulated with antimalarial lipids and
targeted with covalently bound heparin could carry the active agents
in their bilayer membranes with little leaking before reaching their
target site and with low hemorrhagic risk. Although liposomes are
not adequate for the oral formulations currently required to treat
malaria in endemic areas, intravenous administration of drugs might
be a useful approach in a future eradication scenario where the last
cases caused by hyper-resistant parasite strains will be amenable to
treatment with sophisticated, targeted liposomal nanocarriers.
Liposomes have a long record of proven biocompatibility and
their lipid formulation can be adapted to obtain either fast or slow
drug release,8 which makes them adaptable to carrying antimalarial
drugs with diverse pharmacokinetic profiles. (ii) Since resistance of
Plasmodium to heparin has not been shown so far,55 heparin-based
targeting will predictably be more long-lasting than pRBC
recognition relying on antibodies, which typically are raised against
highly variable exposed antigens whose expression is constantly
varied by successive generations of the parasite.56 The specific
binding of CSA to pRBCs infected by theP. falciparum CS2 strain,
which sequester in the maternal circulation of the placenta,57
suggests that future nanovectors functionalized with CSA can be
foreseen to be adapted to target drugs to pRBCs for the treatment of
placental malaria. Such nanocarriers will bypass the concerns
discussed above regarding the hemorrhagic risks of administering
heparin to humans, since CSA has been shown to lack anticoagulant
activity.47 (iii) Finally, the engineering of antimalarial nanomedi-
cines designed to be delivered to mosquitoes and targeted to Plas-
modium stages exclusive to the insect might spectacularly reduce
costs because the clinical trials otherwise required for therapies to be
administered to people could be significantly simplified. Strategies
that control malaria using direct action against Anopheles are not
new, but most of them aim at eliminating the vector, either by killing
it with pesticides58 or through the release of sterile males.59,60 Since
eradicating an insect species might have as a consequence
unpredictable disruptions of ecosystems with potential undesirable
side effects (e.g. crop failure if pollinators were inadvertently
affected), mosquito-friendly antimalarial strategies should be
favored whenever possible. Thus, administration of drugs to
541
542
543Q3
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
10 J. Marques et al / Nanomedicine: Nanotechnology, Biology, and Medicine xx (2016) xxx–xxxmosquitoes to free them of malaria with the objective of blocking
transmission of the disease is a realistic alternative worth exploring.
Acknowledgments
We are indebted to the Cytomics Unit of the Institut
d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)
for technical help, and to Dr. Joan Estelrich (Departament de
Fisicoquímica, Facultat de Farmàcia, Universitat de Barcelona)
for access to liposome assembly facilities.609
610
611
612
613
614Q5
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662U
N
C
O
R
R
E
C
Appendix A. Supplementary data
Supplementary data to this article can be found online at
doi:10.1016/j.nano.2016.09.010.
References
1. Prudêncio M, Rodriguez A, Mota MM. The silent path to thousands of
merozoites: thePlasmodium liver stage.Nat RevMicrobiol 2006;4(11):849-56.
2. Cowman AF, Crabb BS. Invasion of red blood cells by malaria parasites.
Cell 2006;124(4):755-66.
3. Alonso PL, Tanner M. Public health challenges and prospects for malaria
control and elimination. Nat Med 2013;19(2):150-5.
4. Urbán P, Valle-Delgado JJ, Moles E, Marques J, Díez C, Fernàndez-
Busquets X. Nanotools for the delivery of antimicrobial peptides. Curr
Drug Targets 2012;13(9):1158-72.
5. Urbán P, Fernàndez-Busquets X. Nanomedicine against malaria. Curr
Med Chem 2014;21(5):605-29.
6. Kuntworbe N, Martini N, Shaw J, Al-Kassas R. Malaria intervention
policies and pharmaceutical nanotechnology as a potential tool for
malaria management. Drug Dev Res 2012;73:167-84.
7. Baird JK. Effectiveness of antimalarial drugs. N Engl J Med
2005;352(15):1565-77.
8. Moles E, Urbán P, Jiménez-Díaz MB, Viera-Morilla S, Angulo-Barturen
I, Busquets MA, et al. Immunoliposome-mediated drug delivery to
Plasmodium-infected and non-infected red blood cells as a dual
therapeutic/prophylactic antimalarial strategy. J Control Release
2015;210:217-29.
9. Burrows J, van Huijsduijnen R H, Möhrle J, Oeuvray C, Wells T.
Designing the next generation of medicines for malaria control and
eradication. Malar J 2013;12(1):187.
10. Fried M, Duffy PE. Adherence of Plasmodium falciparum to chondroitin
sulfate A in the human placenta. Science 1996;272(5267):1502-4.
11. Andrews KT, Klatt N, Adams Y, Mischnick P, Schwartz-Albiez R.
Inhibition of chondroitin-4-sulfate-specific adhesion of Plasmodium
falciparum-infected erythrocytes by sulfated polysaccharides. Infect
Immun 2005;73(7):4288-94.
12. Baruch DI, Gormley JA, Ma C, Howard RJ, Pasloske BL. Plasmodium
falciparum erythrocyte membrane protein 1 is a parasitized erythrocyte
receptor for adherence to CD36, thrombospondin, and intercellular
adhesion molecule 1. Proc Natl Acad Sci U S A 1996;93(8):3497-502.
13. Reeder JC, Cowman AF, Davern KM, Beeson JG, Thompson JK, Rogerson
SJ, et al. The adhesion of Plasmodium falciparum-infected erythrocytes to
chondroitin sulfate A is mediated by P. falciparum erythrocyte membrane
protein 1. Proc Natl Acad Sci U S A 1999;96(9):5198-202.
14. Valle-Delgado JJ, Urbán P, Fernàndez-Busquets X. Demonstration of
specific binding of heparin to Plasmodium falciparum-infected vs non-
infected red blood cells by single-molecule force spectroscopy. Nanos-
cale 2013;5(9):3673-80.
15. Sheehy TW, Reba RC. Complications of falciparum malaria and their
treatment. Ann Intern Med 1967;66(4):807-9.TE
D
 P
R
O
O
F
16. Marques J, Moles E, Urbán P, Prohens R, Busquets MA, Sevrin C, et al.
Application of heparin as a dual agent with antimalarial and liposome
targeting activities towards Plasmodium-infected red blood cells. Na-
nomedicine: NBM 2014;10:1719-28.
17. Sinden R, Carter R, Drakeley C, Leroy D. The biology of sexual
development of Plasmodium: the design and implementation of
transmission-blocking strategies. Malar J 2012;11(1):70.
18. Ancsin JB, Kisilevsky R. A binding site for highly sulfated heparan sulfate
is identified in the N terminus of the circumsporozoite protein: significance
for malarial sporozoite attachment to hepatocytes. J Biol Chem
2004;279(21):21824-32.
19. Dinglasan RR, Alaganan A, Ghosh AK, Saito A, van Kuppevelt TH,
Jacobs-Lorena M. Plasmodium falciparum ookinetes require mosquito
midgut chondroitin sulfate proteoglycans for cell invasion. Proc Natl
Acad Sci U S A 2007;104(40):15882-7.
20. MathiasDK, Pastrana-MenaR,Ranucci E, TaoD, Ferruti P,OrtegaC, et al.
A small molecule glycosaminoglycan mimetic blocks Plasmodium
invasion of the mosquito midgut. PLoS Pathog 2013;9(11):e1003757.
21. Li F, Templeton TJ, Popov V, Comer JE, Tsuboi T, Torii M, et al.
Plasmodium ookinete-secreted proteins secreted through a common
micronemal pathway are targets of blocking malaria transmission. J Biol
Chem 2004;279(25):26635-44.
22. MacDonald RC, MacDonald RI, Menco BP, Takeshita K, Subbarao NK,
Hu LR. Small-volume extrusion apparatus for preparation of large,
unilamellar vesicles. Biochim Biophys Acta 1991;1061(2):297-303.
23. Urbán P, Estelrich J, Cortés A, Fernàndez-Busquets X. A nanovector with
complete discrimination for targeted delivery to Plasmodium falciparum-
infected versus non-infected red blood cells in vitro. J Control Release
2011;151(2):202-11.
24. Frazier SB, Roodhouse KA, Hourcade DE, Zhang L. The quantification
of glycosaminoglycans: a comparison of HPLC, carbazole, and Alcian
Blue methods. Open Glycosci 2008;1:31-9.
25. Arias JL, López-Viota M, Gallardo V, Ruiz MA. Chitosan nanoparticles
as a new delivery system for the chemotherapy agent tegafur. Drug Dev
Ind Pharm 2010;36(6):744-50.
26. O'Brien RW,White LR. Electrophoretic mobility of a spherical colloidal
particle. J Chem Soc Faraday Trans 1978;2(74):1607-26.
27. Cranmer SL, Magowan C, Liang J, Coppel RL, Cooke BM. An
alternative to serum for cultivation of Plasmodium falciparum in vitro.
Trans R Soc Trop Med Hyg 1997;91(3):363-5.
28. Han ZR, Wang YF, Liu X, Wu JD, Cao H, Zhao X, et al. Fluorescent
labeling of several glycosaminoglycans and their interaction with anti-
chondroitin sulfate antibody. Chin J Anal Chem 2011;39(9):1352-7.
29. Urbán P, Valle-Delgado JJ, Mauro N, Marques J, Manfredi A, Rottmann
M, et al. Use of poly(amidoamine) drug conjugates for the delivery of
antimalarials to Plasmodium. J Control Release 2014;177:84-95.
30. Kirk K. Membrane transport in the malaria-infected erythrocyte. Physiol
Rev 2001;81(2):495-537.
31. Goodyer ID, Pouvelle B, Schneider TG, Trelka DP, Taraschi TF.
Characterization of macromolecular transport pathways in malaria-
infected erythrocytes. Mol Biochem Parasitol 1997;87(1):13-28.
32. Fernàndez-Busquets X. Heparin-functionalized nanocapsules: enabling
targeted delivery of antimalarial drugs. Future Med Chem
2013;5(7):737-9.
33. Beutler E, Duparc S. Glucose-6-phosphate dehydrogenase deficiency and
antimalarial drug development. AmJTrop Med Hyg 2007;77(4):779-89.
34. Burgoine KL, Bancone G, Nosten F. The reality of using primaquine.
Malar J 2010;9(1):376.
35. Chan TK, Todd D, Tso SC. Drug-induced haemolysis in glucose-6-
phosphate dehydrogenase deficiency. BMJ 1976;2:1227-9.
36. Miura Y, Aoyagi S, Kusada Y, Miyamoto K. The characteristics of
anticoagulation by covalently immobilized heparin. J Biomed Mater Res
1980;14(5):619-30.
37. Leitgeb AM, Blomqvist K, Cho-Ngwa F, Samje M, Nde P, Titanji V, et
al. Low anticoagulant heparin disrupts Plasmodium falciparum rosettes
in fresh clinical isolates. AmJTrop Med Hyg 2011;84(3):390-6.
663
664
665Q6
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
728
11J. Marques et al / Nanomedicine: Nanotechnology, Biology, and Medicine xx (2016) xxx–xxx38. Vogt AM, Pettersson F, Moll K, Jonsson C, Normark J, Ribacke U, et al.
Release of sequestered malaria parasites upon injection of a glycosami-
noglycan. PLoS Pathog 2006;2(9):e100.
39. Linhardt RJ, Rice KG, Kim YS, Engelken JD, Weiler JM. Homoge-
neous, structurally defined heparin-oligosaccharides with low anticoag-
ulant activity inhibit the generation of the amplification pathway C3
convertase in vitro. J Biol Chem 1988;263(26):13090-6.
40. Baldrick P. The safety of chitosan as a pharmaceutical excipient. Regul
Toxicol Pharmacol 2010;56(3):290-9.
41. Kean T, Thanou M. Biodegradation, biodistribution and toxicity of
chitosan. Adv Drug Deliv Rev 2010;62(1):3-11.
42. Sinha VR, Singla AK, Wadhawan S, Kaushik R, Kumria R, Bansal K, et
al. Chitosan microspheres as a potential carrier for drugs. Int J Pharm
2004;274(1-2):1-33.
43. Smitskamp H, Wolthuis FH. New concepts in treatment of malignant
tertian malaria with cerebral involvement. Br Med J 1971;1:714-6.
44. Jaroonvesama N. Intravascular coagulation in falciparum malaria. Lan-
cet 1972;1:221-3.
45. Munir M, Tjandra H, Rampengan TH, Mustadjab I, Wulur FH. Heparin
in the treatment of cerebral malaria. Paediatr Indones 1980;20:47-50.
46. World Health Organization Malaria Action Programme. Severe and
complicated malaria. Trans R Soc Trop Med Hyg 1986;80:3-50.
47. Marques J, Vilanova E, Mourão PAS, Fernàndez-Busquets X. Marine
organism sulfated polysaccharides exhibiting significant antimalarial
activity and inhibition of red blood cell invasion by Plasmodium. Sci
Rep 2016;6:24368.
48. Bell GI. Models for the specific adhesion of cells to cells. Science
1978;200:618-27.
49. Evans E, Ritchie K. Dynamic strength of molecular adhesion bonds.
Biophys J 1997;72(4):1541-55.
50. Carvalho PA, Diez-Silva M, Chen H, Dao M, Suresh S. Cytoadherence
of erythrocytes invaded by Plasmodium falciparum: quantitativeU
N
C
O
R
R
E
C
T 727E
D
 P
R
O
O
F
contact-probing of a human malaria receptor. Acta Biomater
2013;9(5):6349-59.
51. AdamsY, FreemanC, Schwartz-Albiez R, FerroV, ParishCR,AndrewsKT.
Inhibition of Plasmodium falciparum growth in vitro and adhesion to
chondroitin-4-sulfate by the heparan sulfate mimetic PI-88 and other sulfated
oligosaccharides. Antimicrob Agents Chemother 2006;50(8):2850-2.
52. Santos-Magalhães NS, Mosqueira VCF. Nanotechnology applied to the
treatment of malaria. Adv Drug Deliv Rev 2010;62(4-5):560-75.
53. Mosqueira VCF, Loiseau PM, Bories C, Legrand P, Devissaguet JP,
Barratt G. Efficacy and pharmacokinetics of intravenous nanocapsule
formulations of halofantrine in Plasmodium berghei-infected mice. An-
timicrob Agents Chemother 2004;48(4):1222-8.
54. Murambiwa P, Masola B, Govender T, Mukaratirwa S, Musabayane CT.
Anti-malarial drug formulations and novel delivery systems: a review.
Acta Trop 2011;118(2):71-9.
55. Boyle MJ, Richards JS, Gilson PR, Chai W, Beeson JG. Interactions
with heparin-like molecules during erythrocyte invasion by Plasmodium
falciparum merozoites. Blood 2010;115(22):4559-68.
56. Kyes S, Horrocks P, Newbold C. Antigenic variation at the infected red
cell surface in malaria. Annu Rev Microbiol 2001;55:673-707.
57. Duffy MF, Maier AG, Byrne TJ, Marty AJ, Elliott SR, O'Neill MT, et al.
VAR2CSA is the principal ligand for chondroitin sulfate A in two
allogeneic isolates of Plasmodium falciparum. Mol Biochem Parasitol
2006;148(2):117-24.
58. Chaccour C, Kobylinski K, Bassat Q, Bousema T, Drakeley C, Alonso P,
et al. Ivermectin to reduce malaria transmission: a research agenda for a
promising new tool for elimination. Malar J 2013;12(1):153.
59. Alphey L, Andreasen M. Dominant lethality and insect population
control. Mol Biochem Parasitol 2002;121(2):173-8.
60. Andreasen MH, Curtis CF. Optimal life stage for radiation sterilization
of Anopheles males and their fitness for release. Med Vet Entomol
2005;19(3):238-44.
U
N
C
O
R
R
E
C
TE
D
 P
R
O
O
F
1 Graphical Abstract
2 Nanomedicine: Nanotechnology, Biology, and Medicine xxx (2016) xxx– xxx
4
5 Adaptation of targeted nanocarriers to changing requirements in
6 antimalarial drug delivery
7
8 Joana Marques, PhDa,b,c, Juan José Valle-Delgado, PhDa,b,c, Patricia Urbán, PhDa,b,c, Elisabet Baró, MSca,b,c, Rafel Prohens, PhDd, Alfredo Mayor, PhDb,
9 Pau Cisteró, BScb, Michael Delves, PhDe, Robert E. Sinden, DSc, FMedScie, Christian Grandfils, PhDf, José L. de Paz, PhDg,
10 José A. García-Salcedo, PhDh, Xavier Fernàndez-Busquets, PhDa,b,c,⁎
11
12
aNanomalaria Group, Institute for Bioengineering of Catalonia (IBEC), Barcelona, Spain
13
bBarcelona Institute for Global Health (ISGlobal), Barcelona Center for International Health Research (CRESIB, Hospital Clínic-Universitat de Barcelona), Barcelona, Spain
14
cNanoscience and Nanotechnology Institute (IN2UB), University of Barcelona, Barcelona, Spain
15
dUnitat de Polimorfisme i Calorimetria, Centres Científics i Tecnològics, Universitat de Barcelona, Barcelona, Spain
16
eDepartment of Life Sciences, Imperial College, South Kensington, London, UK
17
fInterfacultary Research Center of Biomaterials (CEIB), University of Liège, Chemistry Institute, Liège (Sart-Tilman), Belgium
18
gInstituto de Investigaciones Químicas (IIQ) CSIC-US, Centro de Investigaciones Científicas Isla de La Cartuja, Sevilla, Spain
19
hUnidad de Enfermedades Infecciosas y Microbiología, Instituto de Investigación Biosanitaria ibs. Granada, Hospitales Universitarios de Granada/Universidad de Granada, Granada, Spain
20
21 Preexisting antimalarial nanocarriers and targeting molecules (gray boxes) have been modified in their nanocapsule, targeting molecule
22 and drug cargo to adapt them to new therapeutic strategies against malaria parasites
23
24
Nanomedicine: Nanotechnology, Biology, and Medicine
xx (2016) xxx–xxx
nanomedjournal.com
